United States - English - NLM (National Library of Medicine)

physicians total care, inc. - nateglinide (unii: 41x3pwk4o2) (nateglinide - unii:41x3pwk4o2) - nateglinide 120 mg - nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. nateglinide tablets are contraindicated in patients with: - known hypersensitivity to the drug or its inactive ingredients. - type 1 diabetes. - diabetic ketoacidosis. this condition should be treated with insulin.

United States - English - NLM (National Library of Medicine)

avkare - nateglinide (unii: 41x3pwk4o2) (nateglinide - unii:41x3pwk4o2) - nateglinide 60 mg - nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. nateglinide tablets are contraindicated in patients with: - known hypersensitivity to the drug or its inactive ingredients. - type 1 diabetes. - diabetic ketoacidosis. this condition should be treated with insulin.

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - nateglinide (unii: 41x3pwk4o2) (nateglinide - unii:41x3pwk4o2) - nateglinide 60 mg - nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. nateglinide tablets are contraindicated in patients with: - known hypersensitivity to the drug or its inactive ingredients. - type 1 diabetes. - diabetic ketoacidosis. this condition should be treated with insulin.

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - nateglinide (unii: 41x3pwk4o2) (nateglinide - unii:41x3pwk4o2) - nateglinide 60 mg - nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. nateglinide tablets are contraindicated in patients with: - known hypersensitivity to the drug or its inactive ingredients. - type 1 diabetes. - diabetic ketoacidosis. this condition should be treated with insulin.

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - nateglinide (unii: 41x3pwk4o2) (nateglinide - unii:41x3pwk4o2) - nateglinide 60 mg - nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. nateglinide tablets are contraindicated in patients with: - known hypersensitivity to the drug or its inactive ingredients. - type 1 diabetes. - diabetic ketoacidosis. this condition should be treated with insulin.

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - nateglinide (unii: 41x3pwk4o2) (nateglinide - unii:41x3pwk4o2) - nateglinide 60 mg - nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use: nateglinide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. nateglinide is contraindicated in patients with a history of hypersensitivity to nateglinide or its inactive ingredients. risk summary the available data from published literature and the applicant’s pharmacovigilance with use of nateglinide in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). nateglinide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in animal reproduction studies, there was no teratogenicity in rats and rabbits administered oral nategli

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - nateglinide (unii: 41x3pwk4o2) (nateglinide - unii:41x3pwk4o2) - nateglinide 60 mg - nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use: nateglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. nateglinide is contraindicated in patients with a history of hypersensitivity to nateglinide or its inactive ingredients. risk summary the available data from published literature and the applicant's pharmacovigilance with use of nateglinide in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . nateglinide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in animal reproduction studies, there was no teratogenicity in rats and rabbits administered oral na

United States - English - NLM (National Library of Medicine)

american health packaging - nateglinide (unii: 41x3pwk4o2) (nateglinide - unii:41x3pwk4o2) - nateglinide 60 mg - nateglinide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use: nateglinide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. nateglinide tablets are contraindicated in patients with a history of hypersensitivity to nateglinide or its inactive ingredients. pregnancy category c there are no adequate and well-controlled studies of nateglinide in pregnant women. it is unknown whether nateglinide can cause fetal harm when administered to a pregnant woman. nateglinide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in the rabbit, embryonic development was adversely affected and the incidence of gall bladder agenesis or small gallbladder was increased at a dose of 500 mg/kg (approximately 27 times the human therapeutic exposure of 120 mg three times daily, based on body surface area). nateglinide was not terat

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories limited - nateglinide (unii: 41x3pwk4o2) (nateglinide - unii:41x3pwk4o2) - nateglinide 60 mg - nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.   limitations of use : nateglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. nateglinide is contraindicated in patients with a history of hypersensitivity to nateglinide tablets or its inactive ingredients. risk summary the available data from published literature and the applicant’s pharmacovigilance with use of nateglinide in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . nateglinide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in animal reproduction studies, there was no teratogenicity in rats and rabbits adminis

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - nateglinide (unii: 41x3pwk4o2) (nateglinide - unii:41x3pwk4o2) - nateglinide 60 mg - nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use: nateglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. nateglinide is contraindicated in patients with a history of hypersensitivity to nateglinide or its inactive ingredients. pregnancy category c there are no adequate and well-controlled studies of nateglinide in pregnant women. it is unknown whether nateglinide can cause fetal harm when administered to a pregnant woman. nateglinide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in the rabbit, embryonic development was adversely affected and the incidence of gall bladder agenesis or small gallbladder was increased at a dose of 500 mg/kg (approximately 27 times the human therapeutic exposure of 120 mg three times daily, based on body surface area). nateglinide was not terato